Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aeterna Zentaris Inc NDA for Macimorelin Acetate in AGHD accepted for filing by the FDA


Monday, 6 Jan 2014 12:00pm EST 

Aeterna Zentaris Inc:Says the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency (AGHD).Says the acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review. 

Company Quote

0.5329
 --
21 Nov 2014